Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 5,399 matching trials from the live ClinicalTrials.gov search.

Filters: Tucson, Arizona Clear all

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions: Renal Autologous Cell Therapy (REACT); Biological
Lead sponsor: Prokidney; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Tucson, Arizona • Boise, Idaho • Chapel Hill, North Carolina + 1 more

Conditions: Neurotrophic Keratopathy
Interventions: MR-146; Genetic
Lead sponsor: Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Sun City, Arizona • Tucson, Arizona • Glendale, California + 8 more

Conditions: Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions: Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 9
States / cities: Tucson, Arizona • New Haven, Connecticut • Ann Arbor, Michigan + 5 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Mazisotine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more

Conditions: Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 843
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 550 more

Conditions: Asthma
Interventions: Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 18
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: Sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 25 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2007
U.S. locations: 103
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 80 more

Conditions: Heart Failure
Interventions: COGNIS CRT-D; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 81
States / cities: Anchorage, Alaska • Gilbert, Arizona • Little Rock, Arizona + 69 more

Conditions: Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions: cabozantinib, prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 77
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 73 more

Conditions: Geographic Atrophy
Interventions: Lampalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years to 89 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 41
States / cities: Tucson, Arizona • Beverly Hills, California • Campbell, California + 37 more

Conditions: Aging, Medication Adherence, Hypertension
Interventions: Blood Pressure Technology System M, Blood Pressure Technology System E; Other
Lead sponsor: University of Arizona; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Tucson, Arizona • Champaign, Illinois

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: Rivaroxaban, Placebo, Standard of Care (SOC); Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more

Conditions: Barrett's Esophagus
Interventions: Esomeprazole, Lansoprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Phoenix, Arizona • Tucson, Arizona • North Chicago, Illinois + 9 more

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 42
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions: Biphasic Remogliflozin Etabonate, Placebo; Drug · Other
Lead sponsor: BHV Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more

Conditions: Asthma in Overweight Adults
Interventions: Home-Based Aerobic Exercise; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Rosacea
Interventions: Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more

Conditions: Brain and Central Nervous System Tumors
Interventions: Pamiparib, TMZ, Radiation; Drug · Radiation
Lead sponsor: BeiGene USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 18
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more

Conditions: Osteoarthritis
Interventions: Naproxcinod 375 mg bid, Naproxcinod 750 mg bid, Naproxen 500 mg bid, placebo; Drug
Lead sponsor: NicOx; Industry
Eligibility: 40 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 73
States / cities: Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 70 more

Conditions: Foot Ulcer, Diabetic
Interventions: Daily use of podimetrics smart-foot mat; Device
Lead sponsor: Podimetrics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 5 more

Conditions: Cataract, Presbyopia
Interventions: Not listed
Lead sponsor: AcuFocus, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Bakersfield, California • Laguna Hills, California + 17 more

Conditions: Diabetes Mellitus Type 2
Interventions: Aleglitazar, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 7,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 221
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 181 more

Conditions: Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers
Interventions: SF1126; Drug
Lead sponsor: Semafore Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 4
States / cities: Scottsdale, Arizona • Tucson, Arizona • Atlanta, Georgia + 1 more

Conditions: Acute Coronary Syndrome, Sleep Disorder
Interventions: Eszopiclone, Placebo; Drug · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in Participants With Stage 1 or 2 Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Evaluation of Dupilumab in Children With Uncontrolled Asthma

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Evaluation of Multisensor Data in Heart Failure Patients With Implanted Devices

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

Improving Hypertension Medication Adherence for Older Adults

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

Exercise and Asthma in Obese Adults

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers

Post-approval Follow-up Study of the IC-8 Apthera Intraocular Lens (IOL)

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome